News headlines about Nivalis Therapeutics (NASDAQ:ALPN) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies positive and negative press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Nivalis Therapeutics earned a media sentiment score of 0.15 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 46.6934585676576 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
ALPN has been the subject of a number of analyst reports. Zacks Investment Research cut shares of Nivalis Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Thursday, October 26th. Ladenburg Thalmann Financial Services initiated coverage on shares of Nivalis Therapeutics in a research report on Thursday, July 27th. They set a “buy” rating and a $17.00 target price for the company. Finally, ValuEngine cut shares of Nivalis Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, August 2nd. Three research analysts have rated the stock with a sell rating, four have given a hold rating and two have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $5.75.
Shares of Nivalis Therapeutics (NASDAQ:ALPN) traded up $0.50 during trading hours on Tuesday, hitting $10.15. 37,800 shares of the stock traded hands, compared to its average volume of 57,330. Nivalis Therapeutics has a twelve month low of $7.20 and a twelve month high of $26.48.
About Nivalis Therapeutics
Nivalis Therapeutics, Inc is a pharmaceutical company. The Company focuses on the discovery and development of product candidates for patients with cystic fibrosis (CF). Its drug candidate portfolio consists of multiple compounds, which are designed for oral, intravenous (IV) or inhaled administration.
Receive News & Ratings for Nivalis Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nivalis Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.